GOSS Quote, Financials, Valuation and Earnings

Crinetics Pharmaceuticals, Inc. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of -90972.73%. Gossamer Bio, Inc.'s return on equity of -615% beat Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41%.

Gossamer Bio, Inc. has a consensus price target of $9.43, signalling upside risk potential of 311.73%. On the other hand Crinetics Pharmaceuticals, Inc. has an analysts' consensus of $84.08 which suggests that it could grow by 96.9%. Given that Gossamer Bio, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Gossamer Bio, Inc. has a beta of 1.931, which suggesting that the stock is 93.136% more volatile than S&P 500. In comparison Crinetics Pharmaceuticals, Inc. has a beta of 0.195, suggesting its less volatile than the S&P 500 by 80.492%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Crinetics Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than Crinetics Pharmaceuticals, Inc. quarterly revenues of $143K. Gossamer Bio, Inc.'s net income of -$48.2M is higher than Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Crinetics Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 11.81x versus 2,591.22x for Crinetics Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of -39.75%. Gossamer Bio, Inc.'s return on equity of -615% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Gossamer Bio, Inc. has a consensus price target of $9.43, signalling upside risk potential of 311.73%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $671.07 which suggests that it could grow by 44.41%. Given that Gossamer Bio, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Gossamer Bio, Inc. has a beta of 1.931, which suggesting that the stock is 93.136% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Gossamer Bio, Inc.'s net income of -$48.2M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 11.81x versus 13.92x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of --. Gossamer Bio, Inc.'s return on equity of -615% beat Rezolute, Inc.'s return on equity of -67.99%.

Gossamer Bio, Inc. has a consensus price target of $9.43, signalling upside risk potential of 311.73%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.75 which suggests that it could grow by 17.19%. Given that Gossamer Bio, Inc. has higher upside potential than Rezolute, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Rezolute, Inc..

Gossamer Bio, Inc. has a beta of 1.931, which suggesting that the stock is 93.136% more volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.658%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than Rezolute, Inc. quarterly revenues of --. Gossamer Bio, Inc.'s net income of -$48.2M is lower than Rezolute, Inc.'s net income of -$22.8M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 11.81x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of 52.48%. Gossamer Bio, Inc.'s return on equity of -615% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Gossamer Bio, Inc. has a consensus price target of $9.43, signalling upside risk potential of 311.73%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 168.64%. Given that Gossamer Bio, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Gossamer Bio, Inc. is more attractive than XOMA Royalty Corp..

Gossamer Bio, Inc. has a beta of 1.931, which suggesting that the stock is 93.136% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Gossamer Bio, Inc.'s net income of -$48.2M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 32.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 11.81x versus 8.35x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.